In a recent investigation by Upton et al., the synergistic application of anti-CD47 (magrolimab) and anti-HER2 (trastuzumab) antibodies displayed remarkable potential in eradicating HER2+ breast cancer cells, primarily due to the augmentation of ADCP by macrophages. Here, ERBB2 is linked to breast cancer.